5 Ways to Keep Your Kidneys Alive Longer If You Have Diabetes

Your kidneys are working themselves to death right now. And most people with diabetes do not find out until more than half of their kidney function is already gone. When they find out, they ask me how to bring it back. And that's the tough part because it's not coming back. That's the terrifying reality of diabetic kidney disease. It is very silent. It is progressive. And by the time symptoms show up, the damage is already done. Very significant. I'm Dr. Ahmad Ergin. I see this at my clinic every day, again and again. At Diabetes Thyroid and Hormone Center of the Treasure Coast, right here in Port St. Lucie. Patients come in thinking their diabetes is controlled. And then we run the numbers and discover that their kidneys are quietly struggling. They say, oh my primary care checks and nothing is wrong with it. But I'm like, just listen. I'll check in a different way and I'll tell you what it is. The conventional system often catches it so late and offers very limited solutions. And that's not good enough, right? So today, I'm going to give you five science-backed, functionally grounded strategies to protect your kidneys and slow disease progression and maybe even extend the kidney longevity. I will also cover FDA-approved medications that have genuinely changed the game for diabetic kidney disease. Because ignoring the meds or just blaming the meds, I don't want to be on meds, sometimes it's not the best when there's significant damage in your body. So medications have their role. I'm not a medication pusher, but I want you to understand that medications have their role for some patients. Otherwise, it would be a disservice. But everything I'm going to share with you today, I also go deeper. We have a lot of information at sugarmds.com, so you make sure you check that out. We have a lot of blogs there. So for this one, let's start with the foundation. Diabetic kidney disease, also called diabetic nephropathy, affects approximately one in three people with diabetes. It is the leading cause of kidney failure in the United States. The mechanism starts with chronically elevated blood sugar damaging the small blood vessels inside the kidneys. Specifically, the glomeruli, the tiny filtration units. Over time, that damage leads to protein leaking into the urine, inflammation building up, fibrosis setting in, and filtration declining. The standard marker we use is EGFR, estimated glomerular filtration rate, and urine albumin to creatinine ratio, or UACR. When your UACR starts climbing, and your EGFR starts falling, your kidneys are telling you they are under attack. The question is, what you do about it? And the answer is not just medication. It is a comprehensive, functional, whole body approach. Starting with these five strategies. Number one, control blood sugar with precision, not just averages. The single most powerful thing you can do for your kidneys is control your blood sugar. But I want to be very specific about what that means. Because most people, and even most doctors, focus only on A1c and miss the bigger picture. A1c gives you a three month average, but it tells you nothing about blood sugar variability. You can have an A1c of 7, and still have blood sugars spiking to 250 after every meal. Which is generating massive oxidative stress on your kidney tissue every single day. What actually damages kidneys is glucose variability. The peaks and the valleys. More than the sustained average alone. Research published in Diabetes Care has shown that high glucose variability independently predicts diabetic kidney disease progression. Even when A1c is reasonably controlled. This is why continuous glucose monitoring is such a powerful tool. Not just for managing insulin, but for protecting organs. When you can see your post meal glucose response in real time, you can make precise dietary and behavioral adjustments that reduce those damaging spikes. From a functional medicine standpoint, we focus heavily on the postprandial glucose response. What happens in the two hours after a meal? Eating lower glycemic index foods, combining carbohydrates with protein, fiber, and healthy fat to blunt glucose spikes. And timing meals strategically, all reduce the glucose burden on the kidneys. Time-restricted eating has also shown real promise here. A 2023 review in Cell Metabolism demonstrated that time-restricted eating reduced oxidative stress markers and inflammatory cytokines in patients with type 2 diabetes. Both of which directly contribute to kidney damage. Beyond diet, berberine, a plant alkaloid with decades of research behind it, has demonstrated blood sugar lowering effects comparable to metformin in several studies. With an added benefit of improving insulin sensitivity and reducing inflammation in the kidney microenvironment. It activates AMPK, the same energy sensing enzyme that metformin targets. Alpha lipoic acid also plays a dual role here. It improves insulin sensitivity and directly reduces the oxidative stress that accelerates kidney damage. These are not replacements for medication, but they are powerful functional additions. Diabetes is an inflammatory disease. The kidneys are an inflammatory target. Once the glomeruli are damaged by high glucose, the immune system launches a chronic inflammatory cascade. Cytokines like TNF-alpha, IL-6, and IL-1-beta are elevated. Oxidative stress compounds and mesangial cells in the kidney proliferate abnormally, leading to glomerulosclerosis and fibrosis. If you are not actively fighting inflammation, you are letting that process run unchecked. Glutathione, as I have discussed before, is your body's master antioxidant. And it is critically low in people with diabetes. The kidneys are actually one of the highest consumers of glutathione in the body. Because of the enormous metabolic workload they carry. Research published in the Journal of Renal Nutrition has demonstrated that glutathione depletion directly correlates with the severity of diabetic nephropathy. Restoring glutathione levels is not optional in this population. It is essential. This is where the compounding pharmacy conversation becomes critical again. Oral glutathione supplements from retail stores have poor bioavailability. Your gut degrades most of it before it reaches systemic circulation. Compounding pharmacies can prepare glutathione in liposomal, sublingual, intranasal, or injectable forms at therapeutic doses that actually reach the tissue. This is a conversation to have with your functional medicine provider and your compounding pharmacist. Not something to improvise with an Amazon purchase. N-acetylcysteine, or NAC, is another cornerstone of kidney protective antioxidant therapy. NAC is a direct precursor to glutathione and has been studied extensively in kidney disease. It reduces oxidative stress in the tubular cells of the kidney, decreases proteinuria, and has shown nephroprotective effects in multiple clinical studies. Doses used in research typically range from 600 to 1,800 mg daily. Curcumin, the active compound in turmeric, directly inhibits NF-κB, one of the master switches of inflammatory gene expression in the kidney. A meta-analysis published in Phytotherapy Research showed that curcumin supplementation significantly reduced markers of kidney inflammation and oxidative stress in diabetic patients. The challenge with curcumin is bioavailability. You need a formulation with piperine or in a liposomal or phospholipid complex to get meaningful absorption. Omega-3 fatty acids, EPA and DHA from high-quality fish oil, reduce the production of pro-inflammatory eicosanoids, lower triglycerides, and have demonstrated a measurable reduction in urine albumin excretion in diabetic patients in multiple trials. At doses of 2 to 4 grams of combined EPA and DHA daily, Omega-3s represent one of the most accessible and evidence-backed kidney protective supplements available. Hypertension and diabetic kidney disease are inseparable. Elevated blood pressure damages the glomeruli by increasing the hydrostatic pressure inside the filtration units, essentially blowing out the tiny capillaries that do the filtering. Every 10 mmHg reduction in systolic blood pressure translates to a meaningful reduction in kidney disease progression. This is not debatable. The data is overwhelming. The standard of care for blood pressure management in diabetic kidney disease centers on ACE inhibitors and ARBs. Medications like lisinopril, remipril, losartan, and valsartan, these drugs do something unique beyond just lowering blood pressure. They reduce intraglomerular pressure specifically by dilating the efferent arteriole, which directly reduces the mechanical stress on the filtration units. They also reduce proteinuria independently of their blood pressure effects. For anyone with diabetic kidney disease and any degree of aldominuria, ACE inhibitors or ARBs are considered the standard of care and should be on your medication list if they are not already. Now, from a functional standpoint, blood pressure is also driven by inflammation. Oxidative stress. Poor sleep. High sodium intake. Magnesium deficiency. And sympathetic nervous system overdrive. All of which are modifiable. Magnesium plays a pivotal and often overlooked role in blood pressure regulation. It acts as a natural calcium channel blocker, relaxing vascular smooth muscle. Studies show that magnesium supplementation reduces systolic blood pressure by an average of 4-5 mmHg, which is clinically meaningful when combined with other interventions. Most diabetics are magnesium deficient because high blood sugar causes excessive urinary magnesium loss. Magnesium glycinate or magnesium malate are the preferred forms for absorption and tolerability. Dietary sodium reduction remains one of the most powerful non-pharmacological tools for blood pressure and kidney protection. A high sodium diet increases the pressure burden on the kidneys and blunts the effectiveness of both ACE inhibitors and ARBs. Functional medicine practitioners also frequently assess for heavy metal accumulation. Lead and cadmium in particular have well-documented nephrotoxic and hypertensive effects and are often overlooked in conventional workups. Sleep quality is another non-negotiable variable. Obstructive sleep apnea, which is highly prevalent in diabetic patients, generates repeated cycles of hypoxia that activate the renin, angiotensin, and aldosterone system. The same system ACE inhibitors and ARBs target. Untreated sleep apnea undermines every blood pressure intervention you attempt, pharmacological or otherwise. If you have not been evaluated for sleep apnea, that needs to happen. Number four, protect the kidneys with the right medications, including the new ones that are changing everything. I promised to talk about FDA-approved medications, and this conversation is essential, because two drug classes in particular have genuinely revolutionized the management of diabetic kidney disease over the last decade, and they belong in your functional medicine toolbox alongside the lifestyle and supplement strategies. The first is SGLT2 inhibitors. Medications in this class include empagliflozin, dapagliflozin, canagliflozin, and others. These drugs were originally developed to lower blood sugar, but their kidney-protective effects have proven to be extraordinary and largely independent of glucose lowering. The CREDENCE trial with canagliflozin, the DAPA-CKD trial with dapagliflozin, and the EMPA-KIDNEY trial with empagliflozin all demonstrated dramatic reductions in kidney disease progression and kidney failure in diabetic patients. The mechanisms are multifaceted. SGLT2 inhibitors reduce intraglomerular pressure through a process called tubuloglomerular feedback restoration, reduce inflammation and fibrosis within the kidney, lower blood pressure, reduce albuminuria, and have antifibrotic effects on kidney tissue. Dapagliflozin now carries an FDA indication specifically for chronic kidney disease, even in non-diabetic patients. These are not optional considerations. They are game-changing medications that should be discussed with your physician if you have diabetic kidney disease. The second class is GLP-1 receptor agonists. Medications like semaglutide, liraglutide, and dulaglutide, brand names ozempic, victosa, and trulicity, have demonstrated significant kidney protective effects beyond their glucose and weight-lowering properties. The FLOW trial, published in 2024, demonstrated that semaglutide reduced major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease. GLP-1 agonists reduce glomerular inflammation, decrease oxidative stress, reduce albuminuria, and their weight loss effects reduce the mechanical and metabolic burden on the kidneys. Obesity is itself a driver of kidney damage through a mechanism called obesity-related glomerulopathy, and meaningful weight loss reverses some of that damage. More recently, finaranone, a non-steroidal mineralocorticoid receptor antagonist, received FDA approval specifically for reducing kidney disease progression in adults with type 2 diabetes and chronic kidney disease. Unlike older mineralocorticoid antagonists like spironolactone, finaranone was specifically designed to minimize side effects while maximizing kidney and cardiovascular protection. The FIDELIO-DKD trial and the FIGERO-DKD trial demonstrated that finaranone significantly reduced the combined risk of kidney failure and cardiovascular events in this population. What I want you to understand is that these medications and the functional strategies I am describing in this video are not competing with each other. They are complementary. The functional approach creates the biological environment in which medications work better, and the medications provide a level of organ protection that diet and supplements alone cannot fully replicate in advanced disease. At the Diabetes, Thyroid, and Hormone Center of the Treasure Coast, this integrated approach is exactly how we manage our patients. Number five. Address the hidden drivers. Protein load, dehydration, muscle wasting, and the gut-kidney axis. This final strategy is where functional medicine truly separates itself from conventional nephrology, and it covers four interconnected areas that most patients and many physicians never fully address. The first is dietary protein. There is a long-standing conversation in nephrology about protein restriction in kidney disease, and the science has matured significantly. For patients with EGFR below 60, high protein intake, particularly from animal sources, increases glomerular filtration pressure and can accelerate kidney decline. A moderate protein intake of around 0.6 to 0.8 grams per kilogram of body weight has demonstrated benefit in slowing progression in several studies. However, and this is critical for diabetics, too little protein accelerates muscle wasting, worsens insulin resistance, and creates its own metabolic problems. The quality of protein matters enormously. Plant-based proteins, particularly from legumes, soy, and nuts, generate less uremic toxin load than red meat and produce a lower acid load on the kidneys. Reducing red meat consumption is consistently associated with slower kidney disease progression in diabetic populations. The second hidden driver is chronic dehydration. The kidneys regulate fluid balance and concentrate urine, and in a chronically low fluid state, they are working under continuous strain. High blood sugar itself is dehydrating. Osmotic diuresis from glucosuria causes significant fluid and electrolyte loss. Most diabetics are mildly but chronically dehydrated, and this concentrates nephrotoxic substances in the kidney tubules and reduces blood flow to the organ. Simple, consistent hydration. Aiming for pale yellow urine as a guide is a genuinely underrated kidney protective practice. Avoid excessive electrolyte drinks with artificial additives and high potassium supplements without medical guidance, particularly as kidney function declines. The third driver is sarcopenia, muscle wasting. This connection surprises most patients, but skeletal muscle is actually a major site of uremic toxin clearance. Patients with low muscle mass develop uremia faster at the same level of kidney function compared to patients with preserved muscle. Resistance training, lifting weights, or performing bodyweight exercises preserves and builds muscle mass, improves insulin sensitivity, reduces inflammation, and has been directly associated with slower kidney disease progression in diabetic patients. Even two to three sessions per week of moderate resistance training generates meaningful metabolic protection for the kidneys. The fourth, and perhaps most forward-thinking driver, is the gut-kidney axis. The gut microbiome plays a profound role in kidney health, a connection that is now backed by a growing body of research. Dysbiosis, an imbalance in the gut bacterial population, leads to increased production of uremic toxins like indoxyl sulfate and p-cresol sulfate. These toxins are generated when gut bacteria ferment amino acids from protein, particularly in the presence of a low-fiber diet. These toxins enter circulation, damage kidney tubular cells, drive fibrosis, and accelerate kidney decline. In fact, indoxyl sulfate levels are independently predictive of kidney disease progression. Restoring gut health is therefore a legitimate kidney-protective strategy. High-fiber diets, particularly from vegetables, legumes, and whole foods feed beneficial bacteria that produce short-chain fatty acids instead of uremic toxins. Short-chain fatty acids like butyrate are directly anti-inflammatory in the kidney and gut. Specific probiotic strains, including lactobacillus and bifidobacterium species, have shown promise in reducing uremic toxin levels in early clinical studies. Prebiotics from foods like garlic, onions, leeks, asparagus, and resistant starches further support this ecosystem. This is not a fringe approach. The NIH has funded significant research into the gut-kidney axis, and functional medicine practitioners have been applying these principles clinically for years. Putting it all together, your kidneys are not simply failing because of diabetes. They are failing because of high glucose variability, unchecked inflammation, oxidative stress, high blood pressure, and hidden metabolic drivers, and a healthcare system that often waits way too long to act comprehensively. So you do not have to accept that trajectory. Control your blood sugar with precision, number one. Not just A1c, but glucose variability, very important, post-meal spikes, and time and range. Please fight the inflammation and oxidative stress with targeted nutrients like glutathione, but from a compounding pharmacy. NAC as a supplement, get it from high-quality brands. Curcumin, omega-3s. Manage your blood pressure aggressively using both evidence-based medications and functional strategies like magnesium, slim optimization, sodium reduction, and whatnot, everything we talked about. Visit sugarmds.com to understand more about this problem as well. You will have a lot of information and resources. Have a serious conversation with your physician about the SGL-13 inhibitors, GLP-1 receptor agonists, and finerenone, which is carindia. Because if you have diabetic kidney disease and you're not on at least one of these drug classes, you need to ask why and address the hidden drivers like protein quality, hydration, muscle preservation, and your gut microbiome. Because these are the details that determine whether your kidneys survive another decade. So don't just rely on medications. Please listen to my holistic advice. That will help you keep your kidneys a lot longer. Again, I'm Dr. Amit Ergin. So you can find a lot of information, guides, and supplements as well at sugarmds.com. If you're in the Treasure Coast area, we would love to see you at the Diabetes, Thyroid, and Hormones Center of the Treasure. So do not wait for your kidneys to give you symptoms. By then you are already behind. But please leave your questions in the comments, share this with someone that you may need it, and subscribe because this is the kind of medicine that actually saves lives. Talk to you later.